Firms Should Establish Internal Policies For Trial Registry Requirements
This article was originally published in The Gray Sheet
Executive Summary
Companies should develop internal policies in coordination with FDA about how they are going to comply with new clinical trial registration requirements until more formal rulemaking and guidance are available, according to Rebecca Williams, assistant director of the National Institutes of Health 1ClinicalTrials.gov